Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard A Liebman

Showing results (41-50 of 65) with videos related to

Pageof 7
Sort By:
Thrombosis and Haemostasis|August 28, 2002
Chemotherapy-induced activation of hemostasis: effect of a low molecular weight heparin (dalteparin sodium) on plasma markers of hemostatic activationIlene C Weitz, Valerie K Israel, James R Waisman, et al.
Thrombosis Research|October 27, 2009
Increased microparticle tissue factor activity in cancer patients with Venous ThromboembolismDavid A Manly, Jianguo Wang, Sam L Glover, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2009
Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancyJeffrey I Zwicker, Howard A Liebman, Donna Neuberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2006
Unsuspected pulmonary emboli in cancer patients: clinical correlates and relevanceCasey L O'Connell, William D Boswell, Vinay Duddalwar, et al.
British Journal of Haematology|July 9, 2013
Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I studyHoward A Liebman, Mansoor N Saleh, James B Bussel, et al.
Haematologica|August 13, 2016
Comparison of two dosing schedules for subcutaneous injections of low-dose anti-CD20 veltuzumab in relapsed immune thrombocytopeniaHoward A Liebman, Mansoor N Saleh, James B Bussel, et al.
Thrombosis Research|May 1, 2012
Eculizumab therapy results in rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH independent of its effects on hemolysis and microparticle formationIlene C Weitz, Pedram Razavi, Leanne Rochanda, et al.
Gynecologic Oncology|December 25, 2012
Predictive model of venous thromboembolism in endometrial cancerKoji Matsuo, Annie A Yessaian, Yvonne G Lin, et al.
BJU International|August 2, 2008
Subclinical haemostatic activation and current surgeon volume predict bleeding with open radical retropubic prostatectomyScott T Tagawa, Tanya B Dorff, Leanne Rochanda, et al.
Blood|June 8, 2007
A closer look at intravascular hemolysis (IVH) following intravenous anti-D for immune thrombocytopenic purpura (ITP)Michael D Tarantino, James B Bussel, Douglas B Cines, et al.
Pageof 7

Showing results (41-50 of 65) with videos related to

Sort By:
Pageof 7
Thrombosis and Haemostasis|August 28, 2002
Chemotherapy-induced activation of hemostasis: effect of a low molecular weight heparin (dalteparin sodium) on plasma markers of hemostatic activationIlene C Weitz, Valerie K Israel, James R Waisman, et al.
Thrombosis Research|October 27, 2009
Increased microparticle tissue factor activity in cancer patients with Venous ThromboembolismDavid A Manly, Jianguo Wang, Sam L Glover, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2009
Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancyJeffrey I Zwicker, Howard A Liebman, Donna Neuberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2006
Unsuspected pulmonary emboli in cancer patients: clinical correlates and relevanceCasey L O'Connell, William D Boswell, Vinay Duddalwar, et al.
British Journal of Haematology|July 9, 2013
Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I studyHoward A Liebman, Mansoor N Saleh, James B Bussel, et al.
Haematologica|August 13, 2016
Comparison of two dosing schedules for subcutaneous injections of low-dose anti-CD20 veltuzumab in relapsed immune thrombocytopeniaHoward A Liebman, Mansoor N Saleh, James B Bussel, et al.
Thrombosis Research|May 1, 2012
Eculizumab therapy results in rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH independent of its effects on hemolysis and microparticle formationIlene C Weitz, Pedram Razavi, Leanne Rochanda, et al.
Gynecologic Oncology|December 25, 2012
Predictive model of venous thromboembolism in endometrial cancerKoji Matsuo, Annie A Yessaian, Yvonne G Lin, et al.
BJU International|August 2, 2008
Subclinical haemostatic activation and current surgeon volume predict bleeding with open radical retropubic prostatectomyScott T Tagawa, Tanya B Dorff, Leanne Rochanda, et al.
Blood|June 8, 2007
A closer look at intravascular hemolysis (IVH) following intravenous anti-D for immune thrombocytopenic purpura (ITP)Michael D Tarantino, James B Bussel, Douglas B Cines, et al.
Pageof 7